Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1

BACKGROUND: Overexpression of heregulin, a HER3 ligand, is one mechanism that confers resistance to the anti-HER2 agents trastuzumab and lapatinib. We investigated the impact of heregulin expression on the efficacy of HER2-targeted therapeutic agents, including trastuzumab, trastuzumab emtansine (T-...

Descripción completa

Detalles Bibliográficos
Autores principales: Nonagase, Yoshikane, Yonesaka, Kimio, Kawakami, Hisato, Watanabe, Satomi, Haratani, Koji, Takahama, Takayuki, Takegawa, Naoki, Ueda, Hiroto, Tanizaki, Junko, Hayashi, Hidetoshi, Yoshida, Takeshi, Takeda, Masayuki, Chiba, Yasutaka, Tamura, Takao, Nakagawa, Kazuhiko, Tsurutani, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356704/
https://www.ncbi.nlm.nih.gov/pubmed/27768588
http://dx.doi.org/10.18632/oncotarget.12743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356704/
https://www.ncbi.nlm.nih.gov/pubmed/27768588
http://dx.doi.org/10.18632/oncotarget.12743

Ejemplares similares